InDex Pharmaceuticals Holding AB (publ)

SSE:INDEX.ST

0.24 (SEK) • At close February 20, 2024
Bedrijfsnaam InDex Pharmaceuticals Holding AB (publ)
Symbool INDEX.ST
Munteenheid SEK
Prijs 0.244
Beurswaarde 129,975,872
Dividendpercentage 0%
52-weken bereik 0.198 - 0.926
Industrie Biotechnology
Sector Healthcare
CEO Mr. Johan Gileus
Website https://www.indexpharma.com

An error occurred while fetching data.

Over InDex Pharmaceuticals Holding AB (publ)

InDex Pharmaceuticals Holding AB (publ), a pharmaceutical development company, develops pharmaceutical products for patients with ulcerative colitis. The company's lead drug candidate is Cobitolimod, which is in phase III clinical development for the treatment of patients with moderate to severe ulcerative colitis. It also develops a portfolio of other DNA

Vergelijkbare Aandelen

Oncopeptides AB (publ) logo

Oncopeptides AB (publ)

ONCO.ST

7.264 SEK

FluoGuide A/S logo

FluoGuide A/S

FLUO.ST

55.6 SEK

Stille AB logo

Stille AB

STIL.ST

160.5 SEK

Episurf Medical AB (publ) logo

Episurf Medical AB (publ)

EPIS-B.ST

0.98 SEK

Bio-Works Technologies AB (publ) logo

Bio-Works Technologies AB (publ)

BIOWKS.ST

4.85 SEK

Egetis Therapeutics AB (publ) logo

Egetis Therapeutics AB (publ)

EGTX.ST

6.07 SEK

Enzymatica AB (publ) logo

Enzymatica AB (publ)

ENZY.ST

3.05 SEK

Karolinska Development AB (publ) logo

Karolinska Development AB (publ)

KDEV.ST

1.65 SEK

Mendus AB (publ) logo

Mendus AB (publ)

IMMU.ST

0.469 SEK

Financiële Gegevens

Cijfers zijn in miljoenen (SEK)

Cijfers zijn in miljoenen (SEK)